TORONTO & SEOUL, South Korea–(BUSINESS WIRE)–Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to apply Cyclica’s proprietary AI-integrated drug discovery platform in two separate R&D programs. Yuhan is keen on implementing innovative technologies to enhance drug development efforts and will utilize Cyclica’s unique end-to-end AI-integrated drug discovery platform across diverse therapeutic areas to develop novel advanced lead-like molecules with desired chemical properties against the targets of interest determined by Yuhan’s R&D priorities. Yuhan will leverage Cyclica’s integrated drug discovery platform, Ligand DesignTM and Ligand Express® to generate novel



This content is restricted to site members. If you are an existing user, please log in. New users may register too.